Promising Phase 2 Results and Safety Profile Support Buy Rating for BriaCell Therapeutics

Emily Bodnar, an analyst from H.C. Wainwright, has initiated a new Buy rating on BriaCell Therapeutics (BCT).

Emily Bodnar’s rating is based on the promising clinical data and favorable safety profile of BriaCell Therapeutics’ Bria-IMT regimen in treating metastatic breast cancer (mBC). The Phase 2 study results showed a median overall survival (OS) of 13.9 months for patients treated with the Phase 3 formulation, which is notably higher than the outcomes reported for similar patients in existing literature. This is particularly impressive given the heavily pretreated nature of the patient population.
Additionally, the Bria-IMT regimen demonstrated a competitive clinical benefit rate (CBR) of 55% and was well tolerated among patients, with most adverse events being mild to moderate. The treatment showed promising efficacy across various breast cancer subtypes, including ER+/PR+/HER2-, HER2+, and TNBC, with significant improvements in progression-free survival (PFS) and OS. These encouraging results, along with the ongoing Phase 3 trials, underpin Bodnar’s Buy rating for BriaCell Therapeutics.